Anti-C5a Antibody Vilobelimab Does Not Show Statistically Significant Mortality Reduction In Critically Ill, Ventilated Patients With COVID-19 In Trial

MedPage Today (9/16, Hein) reported “an anti-C5a antibody failed to show a statistically significant mortality reduction in critically ill, ventilated” patients with COVID-19 “in a phase III trial, but researchers say the results still point to a benefit...